

Docket No. 372179-338791
US Appln. No. 09/801,908

IN THE CLAIMS

Claim 1 (currently amended): A method for the analgesic treatment of a livestock animal comprising administering to said animal a pharmaceutically effective amount of a palatable caffeine-free aqueous solution said solution comprising ketoprofen and an edible weak base; wherein said solution is not encapsulated [solution of ketoprofen and an oral base in water].

Claim 2 (previously amended): The method of claim 1, wherein the base is selected from the group consisting of sodium bicarbonate, sodium chloride, potassium chloride, sodium sulfate, and potassium sulfate.

Claim 3 (currently amended): The method of claim 1, wherein the solution further comprising the addition of) comprises a flavoring agent.

Claim 4 (currently amended) [The flavoring agent] The method of claim 3 wherein the flavonne agent is selected from the group consisting of cyclohexyl- sulfamic acid, saccharin (o-benzosulfimide), Aspartame (i.e., L-Aspartyl-L-phenylalanine methyl ester), and sugar.

Claim 5 (currently amended): A method for the treatment of rheumatoid arthritis in an animal comprising administering to said animal a pharmaceutically effective amount of a palatable caffeine-free aqueous solution said solution comprising ketoprofen and an edible weak base; wherein said solution is not encapsulated [solution of ketoprofen and an oral base in water].

Claim 6 (currently amended): A method for the treatment of osteoarthritis in an animal comprising administering to said animal a pharmaceutically effective amount of a palatable caffeine-free aqueous solution said solution comprising ketoprofen and an

Docket No. 372179-338791

US Appln. No. 09/801,908

edible weak base; wherein said solution is not encapsulated [solution of ketoprofen and an oral base in water].

Claim 7 (currently amended): A method for the treatment of ankylosing spondylitis in an animal comprising administering to said animal a pharmaceutically effective amount of a palatable caffeine-free aqueous solution said solution comprising ketoprofen and an edible weak base; wherein said solution is not encapsulated [solution of ketoprofen and an oral base in water].

Claim 8 (currently amended): A method for the treatment of acute gouty arthritis in an animal comprising administering to said animal a pharmaceutically effective amount of a palatable caffeine-free aqueous solution said solution comprising ketoprofen and an edible weak base; wherein said solution is not encapsulated [solution of ketoprofen and an oral base in water].

Claim 9 (currently amended): A method for the treatment of acute tendinitis in an animal comprising administering to said animal a pharmaceutically effective amount of a palatable caffeine-free aqueous solution said solution comprising ketoprofen and an edible weak base; wherein said solution is not encapsulated [solution of ketoprofen and an oral base in water].

Claim 10 (currently amended): A method for the treatment of bursitis in an animal comprising administering to said animal a pharmaceutically effective amount of a palatable caffeine-free aqueous solution said solution comprising ketoprofen and an edible weak base; wherein said solution is not encapsulated [solution of ketoprofen and an oral base in water].

Claim 11 (currently amended): A method for the treatment of primary dysmenorrhea in an animal comprising administering to said animal a pharmaceutically effective amount of a palatable caffeine-free aqueous solution said solution comprising ketoprofen and an

Docket No. 372179-338791

US Appln. No. 09/801,908

edible weak base; wherein said solution is not encapsulated [solution of ketoprofen and an oral base in water].

Claim 12 (previously cancelled)

Claim 13 (currently amended): A method for the analgesic treatment of an animal comprising administering to said animal a pharmaceutically effective amount of a caffeine-free non-encapsulated mixture of ketoprofen and an edible weak base, wherein ketoprofen is present [in an amount of 1-10% by weight of a solution and wherein the edible base is present in an amount no greater than about 90% by weight of a solution] in an amount in the range of about 1-10 parts by weight and the edible base is present in an amount no greater than about 90 parts by weight.

Claim 14 (previously amended): The method of claim 13, wherein the edible weak base is selected from the group consisting of sodium bicarbonate, sodium chloride, potassium chloride, sodium sulfate, and potassium sulfate.

Claim 15 (currently amended): The method of claim 13, wherein the non-encapsulated mixture further [comprising the addition of] comprises a flavoring agent.

Claim 16 (currently amended) [The flavoring agent] The method of claim 15 wherein the flavoring agent is selected from the group consisting of cyclohexyl- sulfamic acid, saccharin (o-benzosulfimide), Aspartame (i.e., L-Aspartyl-L-phenylalanine methyl ester), and sugar.

Claim 17 (currently amended): A method for the analgesic treatment of an animal comprising administering to said animal a pharmaceutically effective amount of a caffeine-free non-encapsulated mixture of ketoprofen and an edible weak base, wherein ketoprofen is present [in an amount of 1-10% by weight of a solution and wherein the edible base is present in an amount no greater than about 90% by weight of a solution] in

Docket No. 372179-338791

US Appl. No. 09/801,908

an amount in the range of about 10-20 parts by weight and the edible base is present in an amount no greater than about 80 parts by weight.

Claim 18 (previously amended): The method of claim 17, wherein the edible weak base is selected from the group consisting of sodium bicarbonate, sodium chloride, potassium chloride, sodium sulfate, and potassium sulfate.

Claim 19 (Canceled)

Claim 20 (Canceled)